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Abstract 
 
Background. Depression is a relatively frequent encountered mental disorder in the general 
population, affecting both the quality of the individual life and its ability to perform the social tasks; it is 
generally accepted that new studies related to this pathologic condition are further necessary, in order to 
identify more adequate, efficient and accessible therapeutic compounds. 
Materials and methods. This study was performed on a sample of 60 white male mice, NMRI 
strain, who were divided into 6 groups of 10 animals and treated with 4 new derivatives of dibenzo [a, 
d] cycloheptene, amitriptyline as a reference substance, or with distilled water for the control group. The 
animals were tested in respect to the forced swim test, both before and at 2 hours after administration of 
the mentioned substances. It was determined thus the time of immobilization. 
Results. The study showed the fact that only two of the four investigated compounds presented a 
relatively similar antidepressant effect with the reference substance.  
JMMS 2015, 2(2): 171- 185. Research article 
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Conclusions. Minor structural changes, such as modifications of some substitutes from the basic 
chemical core of the reference substance can decisively influence the conservation or loss of the 
antidepressant properties. 
 
Introduction 
Currently, depression tends to become the most common mental disorder, being present in more 
than 350 million people of all ages, in both women and men from all communities (1). According to a 
study conducted by the World Health Organization, it has been estimated that about 3-15% of the 
general population present a depressive episode every year, of which about 5% suffer from severe 
depressive episodes. Just in Europe for example, 58 subjects from a sample of 1000 adults are affected 
by major depressive disorder, which means a total of 33.4 million affected people (1, 2). 
In 2011, statistics performed by the Ministry of Health revealed that 2739 cases of mental illness 
for 100.000 people have been recorded in Romania, 80% of which were represented by: anxiety, 
depression, neurosis, etc. All of these worrying results justified the fact that depression became currently 
one of the most studied psychiatric disorders. Although there are known several relative efficient 
therapeutic procedures for depression, the access to treatment still remains a problem for many 
countries. According to WHO, in some countries less than 10% of the persons who suffer from 
depression receive an adequate treatment (1, 2). 
Depression is a complex mental disorder with severe implications, in respect not only to the 
patient but also to family and society. The physio-pathologic mechanisms of depression are not fully 
understood, existing however a bio-psycho-social model for depression that is widely accepted by 
researchers and clinicians. This model is based on the idea that the onset of depression is influenced by 
multiple factors such as: the disruption of the biochemical mediators in the brain, psychological 
imbalances of persons with fragile personalities, and possible social factors such as daily stress linked to 
negative events of life, environmental hostility and so on. In almost a quarter of cases the first depressive 
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episode occurs as a reaction to a negative life event, and it may happen again later apparently without 
any reason. It is also documented that depression may be favoured by some neurological disorders such 
as epilepsy, endocrine diseases, infection cases implying HIV/ AIDS, mononucleosis, pneumonia, 
tuberculosis or some cancer types associated with prolonged pain (3, 4). 
 
Materials and Methods 
Depression is usually a temporary and qualitative/ subjective mental disorder, characterized by a 
complex of emotional-affective events that are difficult to be objectively quantified (5). The desperation 
test is a specific way to investigate preclinical the antidepressant action of various compounds, and 
consists in determination of the immobilization time of a mouse which is put in the situation of forced 
swimming. In essence, through this manoeuvre it is intended to induce a similar state (from a 
biochemical perspective) with the state of depression characterised by adreno-serotonergic 
hypofunction. 
Although the Porsolt test is useful in the evaluation of antidepressant action, however it is not very 
objective (6, 7). The test can give false positive results if it is performed using inadequate containers, or 
if the amount of water is incorrectly calculated. This could imply that the mice can cling with the 
anterior paws to the lateral sides or can reach with the hind paws to bottom, or can jump out. To avoid 
these possibilities it is recommended to use cylinders with smooth walls and having 30 cm in diameter, 
the depth of the water column to be at least 10 cm, and the distance from the water to the edge of the 
cylinder should not be lesser than 10 cm. 
Materials 
- Mice, NMRI (Naval Medical Research Institute), weighing between 18-25 g; 
- standardized nutritional grains from cereals; 
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- substances to be tested: derivatives of dibenzo [a, d] cycloheptene (8), synthesized in the Department 
of Organic Chemistry at the "Carol Davila" Faculty of Pharmacy, Bucharest (C1, C2, C3, C4), reference 
substance (amitriptyline) (9), and control (distilled water); 
- transparent cages from Plexiglas, lined with wood shavings; 
- transparent glass cylinder (30 cm diameter, 24 cm height) containing water (at 22˚C, until a height of 
15 cm);  
- electronic balance; syringes 
Methods 
 The animals were transported from the designed department of "Carol Davila University" with 5 
days prior the onset of the experiment, in order to allow their acclimatisation to the new environment 
(receiving food and water "ad libitum", the ambient temperature was 22-23˚C, and the animals were 
exposed to a standard cycle of light/ dark). 
 Animals were brought into the room where the experiment was performed with 60 minutes prior to 
the start of it, for adjustment. The study deployed on groups of 10 animals, relatively similar in terms of 
biometric characteristics (mass, age, sex). 
 The initial tests were performed, leading to delineation of animals on distinct lots, according to the 
times of immobilization registered in this stage. The animals were weighed, and received the substances 
(C1, C2, C3, C4, amitriptyline, control), orally 60 minutes before the test. 
The study was performed with 6 groups of 10 mice, as follows: 
Sample 1: control (distilled water), at a dose of 0.1ml / 10g orally 
Sample 2: Reference-amitriptyline susp. 1%, at a dose of 100 mg / kg orally 
Sample 3: C1 substance susp. 1%, at a dose of 100 mg / kg orally  
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Sample 4: C2 substance susp. 1%, at a dose of 100 mg / kg orally 
Sample 5: C3 substance susp. 1%, at a dose of 100 mg / kg orally 
Sample 6: C4 substance susp. 1%, at a dose of 100 mg / kg orally 
 The animals were placed within cylinders and followed by the same observer for 6 minutes: during 
the last four minutes the total duration of immobilization was recorded, being obtained by summing the 
periods of time during which the animal stands still; the movements made by animal to maintain the 
head above the water were not taken into account. Data obtained from the treated groups were 
statistically analysed and compared with control and reference groups. 
 All procedures were performed respecting the rules of bioethics in research on experimental animals 
for scientific purposes, in accordance with Law 43/2014 on the protection of animals used for scientific 
purposes and Directive 2010/63 / EU of the European Parliament and of the Council of Europe - 
September 22, 2010 on protection of animals used for scientific purposes. 
 The overall interpretation of the results was carried out by applying the statistical t test - Student to 
compare two columns with normal distribution, and ANOVA to compare more than two columns with 
normal distribution. The statistical test ANOVA was followed by Dunnett's post-test, for the event of a 
possible statistical significance. Normal or abnormal distribution of the data was determined by the 
D`Agostino – Pearson test. All these tests were performed using Graph Pad Prism software version 5.01, 
and for the graphics Microsoft Office Excel, 2007 version was used.  
 The effect (%) over time of immobilisation was calculated as the difference between the initial and 
final time of restraint, in rapport to the initial time of immobilization, as follow: 
Tf−Ti 
Ef %= ——— X 100 
Ti 
Where: Ef% - effect on the time of immobilization, % 
Ti - initially time of immobilization 
Tf – final time of immobilization 
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Results 
Table 1. Evolution of immobilization time for despair test obtained in the control group 
No. 
Initial time of immobilization 
(s) 
Final time of immobilization 
(s) 
1 45 51 
2 42 54 
3 65 70 
4 74 76 
5 56 62 
6 80 60 
7 76 71 
8 46 55 
9 66 80 
10 80 74 
Mean ± EMS 63 ± 4,695 65,3 ± 3,229 
DS 14,85 10,21 
Normal distribution (D`Agostino – Pearson 
test) 
Yes Yes 
Effect (%) vs. Initial data - -3,65% 
t-Student test p > 0,05 
 
 Table 2. Evolution of immobilization time for despair test obtained in the group C1 
No. 
Initial time of immobilization 
(s) 
Final time of immobilization 
(s) 
1 55 42 
2 86 66 
3 81 41 
4 77 37 
5 76 42 
6 62 55 
7 49 43 
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8 78 35 
9 84 69 
10 69 48 
Mean ± EMS 71,7 ± 3,978 47,8 ± 3,726 
DS 12,58 11,78 
Normal distribution (D`Agostino – Pearson 
test) 
Yes Yes 
Effect (%) vs. Initial data - -33,33% 
t-Student test p < 0,001 
 
Table 3. Evolution of immobilization time for despair test obtained in the group C2 
No. 
Initial time of immobilization 
(s) 
Final time of immobilization 
(s) 
1 76 72 
2 59 51 
3 64 59 
4 56 45 
5 51 46 
6 80 77 
7 53 61 
8 42 58 
9 57 42 
10 56 64 
Mean ± EMS 59,4 ± 3,597 57,5 ± 3,68 
DS 11,37 11,64 
Normal distribution (D`Agostino – Pearson 
test) 
Yes Yes 
Effect (%) vs. Initial data - -3,2% 
t-Student test p > 0,05 
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Table 4. Evolution of immobilization time for despair test obtained in the group C3 
No. 
Initial time of immobilization 
(s) 
Final time of immobilization 
(s) 
1 76 57 
2 56 45 
3 42 47 
4 67 79 
5 48 62 
6 50 54 
7 74 81 
8 53 49 
9 69 81 
10 54 47 
Mean ± EMS 58,9 ± 3,71 60,2 ± 4,685 
DS 11,73 14,82 
Normal distribution (D`Agostino – Pearson 
test) 
Yes Yes 
Effect (%) vs. Initial data - +2,21% 
t-Student test p > 0,05 
 
Table 5. Evolution of immobilization time for despair test obtained in the group C4 
No. 
Initial time of immobilization 
(s) 
Final time of immobilization 
(s) 
1 69 62 
2 74 47 
3 48 35 
4 66 53 
5 58 41 
6 67 54 
7 71 50 
8 78 54 
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9 77 49 
10 76 64 
Mean ± EMS 68,48 ± 2,971 50,9 ± 2,767 
DS 9,395 8,749 
Normal distribution (D`Agostino – Pearson 
test) 
Yes Yes 
Effect (%) vs. Initial data - -25,67% 
t-Student test p < 0,001 
 
Table 6. Evolution of immobilization time for despair test obtained in the reference group 
No. 
Initial time of immobilization 
(s) 
Final time of immobilization 
(s) 
1 60 36 
2 78 48 
3 51 33 
4 69 29 
5 71 20 
6 55 45 
7 63 40 
8 57 32 
9 48 22 
10 53 26 
Mean ± EMS 60,5 ± 3,056 33,1 ± 2,949 
DS 9,664 9,327 
Normal distribution (D`Agostino – Pearson 
test) 
Yes Yes 
Effect (%) vs. Initial data - -45,29% 
t-Student test p < 0,0001 
 
Table 7. Evolution of immobilization time for despair test obtained in the control group 
No. Initial time of Initial time Initial time Initial time Initial time Initial time of 
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immobiliz 
control 
of immobiliz 
C1 
of immobiliz 
C2 
of immobiliz 
C3 
of immobiliz 
C4 
immobiliz 
reference 
Mean ± EMS 63 ± 4,695 71,7 ± 3,978 59,4 ± 3,597 58,9 ± 3,71 
68,48 ± 
2,971 
60,5 ± 3,056 
DS 14,85 12,58 11,37 11,73 9,395 9,664 
Normal 
Distribution 
(D`Agostino 
Pearson test) 
Yes Yes Yes Yes Yes Yes 
Effect% vs. 
control 
- +13,81% -5,71% -6,51% +8,7% 
 
-3,97% 
ANOVA test p > 0,05 
Dunett  
post test 
- NS NS NS NS NS 
 
Table 8. Evolution of final immobilization time for despair test obtained in the control group 
No. 
Final 
 time of 
immobiliz 
control 
Final 
 time of 
immobiliz 
C1 
Final 
 time of 
immobiliz 
C2 
Final time of 
immobiliz 
C3 
Final time of 
immobiliz 
C4 
Final time of 
immobiliz 
reference 
Mean ± EMS 65,3 ± 3,229 47,8 ± 3,726 57,5 ± 3,68 60,2 ± 4,685 50,9 ± 2,767  33,1 ± 2,949 
DS 10,21 11,78 11,64 14,82 8,749 9,327 
Normal 
Distribution 
(D`Agostino 
Pearson test) 
Yes Yes Yes Yes Yes Yes 
Effect% vs. 
control 
- -26,8% -11,95% -7,81% -22,05% -49,31% 
ANOVA test p < 0,0001 
Dunett  
post test 
- ** NS NS * *** 
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Figure 1 Figure 2 
 
  
 
Discussions 
Depression is a mental disorder that has implication not only in cognitive- behavioural processes, 
but also in the functioning of the body as a whole (10). It can be defined as a declining of the general/ 
basal well-being, often reiterating unpleasant, sad and threatening feelings. Depressive syndrome is 
characterized by absence of the good mood, slowing of the thought processes, psychomotor slowness 
and, in addition, clinical expression of a various auxiliary somatic symptoms (5). 
The biochemical theories in respect to the etiopathogeny of depression usually refer especially to 
the model of endogenous depression (that is the primary depression major), and present several 
hypotheses: 
The monoamine deficiency theories suggest that there is a deficiency on the transmission line of 
one of the cerebral neurotransmitters, referring either to noradrenaline (NA) or the serotonin (5-HT). 
These theories take into considerations only the quantitative deficiency of the neuromodulators implied, 
leading to a division of the endogenous/ biochemical depression into two distinct subgroups: through 
deficiency of serotonin, or through deficiency of norepinephrine; the dosage for each of these 
neurotransmitters metabolites shows low levels in the depressed patients (1, 3). 
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Dopamine (DA) has also been incriminated in some types of depression, an idea supported by an 
increased frequency of depressive episodes occurring during the evolution of Parkinson's disease. 
However, the dopamine deficiency may be invoked as a pathogenic mechanism only to a limited group 
of patients, presenting dopamine-dependent depression (1, 3). 
The imbalance theory between the transmission pathways of various neuromodulators assumes that 
there is an imbalance between NA and 5-HT, the level of NA decreasing while the level of serotonine 
increasing. Such disruption could result from a possible competitive action of the two precursors at the 
blood brain barrier, namely tyrosine (for NA) and tryptophan (for 5-HT). The implications of different 
cerebral neurotransmitters in clinical manifestations of depression are the main etiopathogenic 
arguments supporting the psychopharmacological models (4). 
From a pharmacological perspective, antidepressants that are used currently can be classified in 
the following groups based on their mechanism of action (11): 
► adrenaline, noradrenaline and/ or serotonin reuptake inhibitors  
► adrenergic and serotonergic receptor antagonists 
► monoaminoxidaze inhibitors 
1. The reuptake inhibitors of synaptic transmission are: 
● non-selective reuptake inhibitors of norepinephrine and serotonine (amitriptyline, nortriptyline, 
imipramine, doxepin)  
● non-selective reuptake inhibitors of serotonin and dopamine (venlafaxine) 
● non-selective reuptake inhibitors of  noradrenaline and dopamine (amfebutamona) 
● selective noradrenaline reuptake inhibitors (maprotiline oxaprotiline, dezipramina, reboxetine 
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● selective serotonin reuptake inhibitors (sertraline, fluoxetine, paroxetine, citalopram, 
fluvoxamine) 
2. The adrenergic and serotonergic receptor antagonists are: 
● α2 presynaptic receptor antagonists (mirtazapine) 
● selective 5HT2 receptor antagonists, α2 and H1 (mianserin) 
3. The monoaminoxidaze inhibitors can be: 
● non-selective and irreversible inhibitors (nialamide, phenelzine) 
● selective and reversible inhibitors of monoamine oxidase A (moclobemide) 
The compounds investigated in this study presents a dibenzo [a, d] cycloheptene chemical core, 
which is structurally similar to amitriptyline. It was studied here if/ how the minor structural variations 
of the mentioned chemical core can influence the antidepressant action. 
Data obtained here showed that the administration of the investigated compounds leads to 
different periods for immobilization time. The compounds C1 and C4 induced a shorter immobilization 
time compared to initial time –33.33%, respectively –25.67% (statistically significant for Student-t test). 
Compared to control, decreases were –26.8% for C1, respectively –22.05% for C4. The compounds C2 
and C3 lead to minor changes for immobilization time compared with initial time, namely –3.2%, 
respectively +2.21% (statistically insignificant for Student-t test). Compared to control, a decreasing of 
immobilization time with –11.95% for C2, respectively with –7.81% for C3 was recorded. 
Analysing the initial immobilization times for all groups, a statistically insignificant variation of 
ANOVA test was observed which in fact an expression of the normal inter-individual variability is. The 
ANOVA test applied in order to compare the final immobilization times obtained after administration of 
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investigational compounds with the immobilization time of the control, highlight the statistical 
significance of the decreasing periods reordered after administration of C1 and C4.  
 
Conclusion 
According to our data, only two of the four studied compounds maintain their antidepressant 
properties. Due to the fact that all compounds incorporates a dibenzo [a, d] cycloheptene chemical core, 
it can be concluded that their substituents have a decisive role in preserving or losing the antidepressant 
properties. 
New studies are necessary in order to further highlight possible advantages (in terms of 
pharmacokinetics and pharmacotoxicology) of the four compounds investigated here, in comparison 
with the already existing compounds on the pharmaceutical market. 
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